Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IDYA | 39.75% | $2.15B | -32.66% | 0.00% |
ALDX | 36.15% | $304.30M | +52.99% | 0.00% |
GIII | 36.06% | $1.41B | +0.85% | 0.00% |
IMVT | 35.81% | $3.47B | -45.40% | 0.00% |
MMI | 34.66% | $1.35B | -7.77% | 1.49% |
CERS | 34.35% | $302.72M | -19.31% | 0.00% |
SDGR | 34.34% | $1.48B | -33.10% | 0.00% |
SHEN | 34.17% | $685.26M | -39.17% | 0.83% |
EDIT | 33.63% | $110.61M | -85.84% | 0.00% |
MGTX | 33.32% | $496.27M | -6.48% | 0.00% |
KYMR | 32.98% | $2.62B | +39.20% | 0.00% |
ORKA | 32.71% | $665.32M | +75.33% | 0.00% |
SPSC | 32.59% | $6.89B | +3.01% | 0.00% |
JOE | 32.57% | $2.57B | -22.91% | 1.19% |
PTGX | 32.44% | $2.24B | +43.59% | 0.00% |
SNDX | 31.50% | $1.18B | -38.89% | 0.00% |
CRSP | 31.44% | $3.52B | -34.81% | 0.00% |
ALEX | 31.43% | $1.26B | -5.31% | 5.26% |
ARCT | 31.30% | $513.31M | -44.59% | 0.00% |
PRTA | 31.30% | $761.93M | -60.52% | 0.00% |
Current Value
$3.331 Year Return
Current Value
$3.331 Year Return
SeekingAlpha
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Yahoo
Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for Q3 2024 and 13.8% year-t0-date while the S&P 500 Index returned 5.9% and 9.3%, respectively. In addition, please check the fund’s top five holdings to know […]
Yahoo
NEW YORK, December 03, 2024--Whitefort Capital Management, LP (together with its affiliates, "Whitefort Capital," "us" or "we"), which is a long-term investor and the third largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) ("Arbutus" or the "Company") with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published a letter to the Company’s Board of Directors (the "Board") outlining its views on the actions Arbutus must take in order to preserve a
Yahoo
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET. To access the live webcast of t
Finnhub
WARMINSTER - Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B...
Finnhub
The Liver Meeting 2024.The new data are from an additional cohort of participants who received repeat doses of imdusiran, Arbutus' RNAi therapeutic, followed by Barinthus Bio's T-cell stimulating...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HUSA | -16.20% | $20.15M | -6.10% | 0.00% |
MCK | -14.48% | $74.93B | +22.03% | 0.45% |
MNR | -14.27% | $1.77B | +2.64% | 18.75% |
TXO | -9.91% | $686.93M | -11.63% | 14.06% |
XOM | -9.27% | $469.97B | +8.35% | 3.61% |
RLMD | -9.26% | $13.64M | -86.59% | 0.00% |
LPTH | -8.93% | $130.89M | +164.00% | 0.00% |
ARLP | -8.92% | $3.38B | +20.30% | 10.44% |
DMLP | -8.25% | $1.60B | +10.07% | 10.40% |
K | -7.72% | $28.11B | +46.16% | 2.77% |
LNG | -7.66% | $50.52B | +34.73% | 0.80% |
OXY | -7.18% | $48.03B | -9.88% | 1.70% |
TTC | -7.13% | $8.02B | -12.80% | 1.88% |
BEST | -7.03% | $31.63M | +7.56% | 0.00% |
CPB | -7.00% | $11.69B | -10.27% | 3.95% |
HES | -6.85% | $43.08B | +0.64% | 1.33% |
OCFT | -6.58% | $91.98M | -13.49% | 0.00% |
ABBV | -6.48% | $315.43B | +8.25% | 3.51% |
PRPO | -6.16% | $9.23M | +5.03% | 0.00% |
SUN | -6.05% | $7.13B | -9.58% | 6.75% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CHD | -<0.01% | $25.13B | +6.31% | 1.12% |
ODD | -0.01% | $2.47B | -2.23% | 0.00% |
VHC | -0.05% | $26.48M | +14.70% | 0.00% |
NEUE | 0.08% | $61.25M | -38.83% | 0.00% |
GILD | -0.08% | $111.09B | +5.49% | 3.44% |
COR | 0.10% | $45.97B | +10.04% | 0.87% |
AON | 0.12% | $76.22B | +17.76% | 0.75% |
QXO | 0.13% | $6.26B | -86.07% | 0.00% |
LGF.A | -0.15% | $2.00B | -19.73% | 0.00% |
CIVI | -0.17% | $4.72B | -21.19% | 3.91% |
CME | 0.21% | $82.63B | +15.91% | 4.55% |
PGR | -0.21% | $142.70B | +47.18% | 0.49% |
NEXA | -0.26% | $916.48M | 0.00% | 0.00% |
RDDT | 0.27% | $30.20B | +405.91% | 0.00% |
VSTA | 0.27% | $184.39M | -44.44% | 0.00% |
HAL | -0.30% | $23.75B | -20.66% | 2.51% |
BKR | 0.32% | $42.99B | +39.10% | 1.95% |
CEG | -0.35% | $76.27B | +110.48% | 0.47% |
MRNS | -0.41% | $29.38M | -94.93% | 0.00% |
MPC | -0.44% | $45.74B | -6.88% | 2.37% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CANE | -0.34% | $12.08M | 0.29% |
FBY | 0.56% | $165.62M | 0.99% |
DUSB | 0.66% | $923.39M | 0.15% |
GCC | 0.83% | $131.62M | 0.55% |
SUB | 0.84% | $8.65B | 0.07% |
FCG | 0.97% | $412.27M | 0.6% |
ICLO | 1.01% | $287.21M | 0.2% |
RSPG | -1.10% | $531.40M | 0.4% |
IEO | -1.14% | $584.26M | 0.4% |
GBIL | 1.33% | $5.84B | 0.12% |
BCI | -1.42% | $1.31B | 0.26% |
FTXN | -1.43% | $159.83M | 0.6% |
BCD | -1.52% | $233.79M | 0.3% |
PXE | 1.83% | $103.41M | 0.63% |
DBA | -2.18% | $794.04M | 0.93% |
IYE | -2.19% | $1.29B | 0.39% |
BIL | 2.29% | $36.56B | 0.1356% |
XOP | 2.29% | $2.26B | 0.35% |
CHIQ | 2.29% | $204.20M | 0.65% |
IBTF | 2.31% | $2.23B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBE | -16.06% | $48.32M | 0.77% |
DBO | -14.50% | $216.94M | 0.77% |
USDU | -14.16% | $379.83M | 0.5% |
VIXY | -13.58% | $195.31M | 0.85% |
UUP | -13.55% | $603.95M | 0.77% |
COMT | -11.71% | $694.40M | 0.48% |
CORN | -11.15% | $63.58M | 0.2% |
GSG | -11.08% | $1.02B | 0.75% |
UNG | -10.30% | $746.57M | 1.06% |
PDBC | -9.73% | $4.17B | 0.59% |
USCI | -9.55% | $194.60M | 1.07% |
KRBN | -8.81% | $199.62M | 0.85% |
DBC | -8.43% | $1.31B | 0.87% |
KCCA | -8.02% | $119.57M | 0.87% |
TPMN | -7.80% | $41.62M | 0.65% |
FLTR | -7.60% | $1.95B | 0.14% |
AGZD | -6.79% | $142.56M | 0.23% |
SOYB | -6.66% | $24.83M | 0.22% |
TAIL | -5.68% | $65.56M | 0.59% |
FTGC | -4.42% | $2.24B | 1.02% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 43.07% | $6.39B | 0.35% |
PTH | 40.23% | $122.57M | 0.6% |
ARKG | 38.71% | $1.16B | 0.75% |
IBB | 38.35% | $6.59B | 0.45% |
XPH | 37.83% | $158.74M | 0.35% |
IWC | 37.68% | $965.33M | 0.6% |
IWO | 36.59% | $12.83B | 0.24% |
GNOM | 36.32% | $71.12M | 0.5% |
VTWO | 36.16% | $12.40B | 0.1% |
IWM | 36.10% | $72.22B | 0.19% |
ISCG | 35.34% | $641.73M | 0.06% |
NUSC | 34.92% | $1.24B | 0.31% |
PRFZ | 34.79% | $2.56B | 0.39% |
IWN | 34.65% | $12.27B | 0.24% |
KOMP | 34.49% | $2.13B | 0.2% |
IJR | 34.33% | $87.64B | 0.06% |
FBT | 34.22% | $1.13B | 0.56% |
SMMD | 34.21% | $1.37B | 0.15% |
SPSM | 34.07% | $12.42B | 0.03% |
IJS | 34.04% | $7.51B | 0.18% |